EA201600124A1 - Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их - Google Patents

Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их

Info

Publication number
EA201600124A1
EA201600124A1 EA201600124A EA201600124A EA201600124A1 EA 201600124 A1 EA201600124 A1 EA 201600124A1 EA 201600124 A EA201600124 A EA 201600124A EA 201600124 A EA201600124 A EA 201600124A EA 201600124 A1 EA201600124 A1 EA 201600124A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
indolesine
new
production
pharmaceutical compositions
Prior art date
Application number
EA201600124A
Other languages
English (en)
Other versions
EA030323B1 (ru
Inventor
Арно Ле Тиран
Тьерри Ле Дигаре
Жером-Бенуа Старк
Жан-Мишель Анлен
Гийом Де Нантёй
Оливье Жанест
Джеймс Эдуард Пол Дейвидсон
Джеймс Брук Марри
Ицзень Чэнь
Original Assignee
Ле Лаборатуар Сервье
Верналис (Эр&Ди) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье, Верналис (Эр&Ди) Лимитед filed Critical Ле Лаборатуар Сервье
Publication of EA201600124A1 publication Critical patent/EA201600124A1/ru
Publication of EA030323B1 publication Critical patent/EA030323B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединения формулы (I), в которой R, R, R, R, T, R, R, R, X, Y и Het являются такими, как определено в описанииЛекарственные средства.
EA201600124A 2013-07-23 2014-07-22 Индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их EA030323B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357265A FR3008976A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
PCT/FR2014/051885 WO2015011397A1 (fr) 2013-07-23 2014-07-22 Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA201600124A1 true EA201600124A1 (ru) 2016-07-29
EA030323B1 EA030323B1 (ru) 2018-07-31

Family

ID=50023640

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600124A EA030323B1 (ru) 2013-07-23 2014-07-22 Индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их

Country Status (49)

Country Link
US (3) US9944620B2 (ru)
EP (1) EP3024833B1 (ru)
JP (1) JP6458029B2 (ru)
KR (1) KR102007516B1 (ru)
CN (1) CN105579450B (ru)
AP (1) AP2016008990A0 (ru)
AR (1) AR099913A1 (ru)
AU (1) AU2014294867B2 (ru)
BR (1) BR112016001328B1 (ru)
CA (1) CA2918217C (ru)
CL (1) CL2016000063A1 (ru)
CR (1) CR20160031A (ru)
CU (1) CU24380B1 (ru)
CY (1) CY1119652T1 (ru)
DK (1) DK3024833T3 (ru)
DO (1) DOP2016000014A (ru)
EA (1) EA030323B1 (ru)
ES (1) ES2650814T3 (ru)
FR (1) FR3008976A1 (ru)
GT (1) GT201600017A (ru)
HK (2) HK1222394A1 (ru)
HR (1) HRP20171752T1 (ru)
HU (1) HUE037498T4 (ru)
IL (1) IL243742B (ru)
JO (1) JO3310B1 (ru)
LT (1) LT3024833T (ru)
MA (1) MA38803A1 (ru)
MD (1) MD4643C1 (ru)
ME (1) ME02922B (ru)
MX (1) MX365916B (ru)
MY (1) MY178251A (ru)
NI (1) NI201600015A (ru)
NO (1) NO3024833T3 (ru)
NZ (1) NZ716156A (ru)
PE (1) PE20160240A1 (ru)
PH (1) PH12016500057A1 (ru)
PL (1) PL3024833T3 (ru)
PT (1) PT3024833T (ru)
RS (1) RS56451B1 (ru)
RU (1) RU2693629C2 (ru)
SA (1) SA516370448B1 (ru)
SG (2) SG11201600318RA (ru)
SI (1) SI3024833T1 (ru)
TN (1) TN2016000014A1 (ru)
TW (1) TWI511969B (ru)
UA (1) UA119243C2 (ru)
UY (1) UY35626A (ru)
WO (1) WO2015011397A1 (ru)
ZA (1) ZA201600350B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
EP3969639A1 (en) * 2019-05-13 2022-03-23 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
UY39670A (es) 2021-03-12 2022-07-29 Eil Therapeutics Inc Compuestos que tienen tetrahidroindolizina-1-carboxamida como inhibidores de bcl-2
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
AU2005277223C1 (en) * 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
CN101356159A (zh) 2005-12-22 2009-01-28 惠氏公司 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
AU2008242983B2 (en) 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
ES2537803T3 (es) 2007-05-22 2015-06-12 Astellas Pharma Inc. Compuesto de tetrahidroisoquinolina 1-sustituida
JP2011518109A (ja) 2007-11-30 2011-06-23 ビオタ サイエンティフィック マネージメント ピーティーワイ リミテッド 抗菌剤としてのテトラヒドロ−イソキノリンppat阻害剤
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
CA2715373C (en) 2008-02-15 2019-11-05 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EP2714681B1 (en) * 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
US20140350014A1 (en) 2011-12-23 2014-11-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859862A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096055A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CN104125954A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
DK2609926T3 (da) 2011-12-30 2014-01-06 Jakob Hraschan Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CN105579450B (zh) 2017-12-12
MX2016000906A (es) 2016-05-05
NI201600015A (es) 2016-02-11
SA516370448B1 (ar) 2018-12-12
CY1119652T1 (el) 2018-04-04
AP2016008990A0 (en) 2016-01-31
UA119243C2 (uk) 2019-05-27
CU24380B1 (es) 2019-02-04
UY35626A (es) 2015-02-27
DOP2016000014A (es) 2016-03-15
IL243742A0 (en) 2016-04-21
HUE037498T2 (hu) 2018-08-28
MD20160016A2 (ru) 2016-07-31
HK1223360A1 (zh) 2017-07-28
HRP20171752T1 (hr) 2017-12-29
ES2650814T3 (es) 2018-01-22
CL2016000063A1 (es) 2016-08-19
NZ716156A (en) 2019-05-31
CA2918217A1 (fr) 2015-01-29
MY178251A (en) 2020-10-07
HUE037498T4 (hu) 2018-11-28
AU2014294867B2 (en) 2018-10-04
MA38803A1 (fr) 2017-10-31
JP6458029B2 (ja) 2019-01-23
NO3024833T3 (ru) 2018-02-03
US20190359595A1 (en) 2019-11-28
FR3008976A1 (fr) 2015-01-30
GT201600017A (es) 2018-10-08
SG10201800580XA (en) 2018-03-28
US9944620B2 (en) 2018-04-17
US20160176848A1 (en) 2016-06-23
KR20160034387A (ko) 2016-03-29
HK1222394A1 (zh) 2017-06-30
RU2016105999A (ru) 2017-08-28
CN105579450A (zh) 2016-05-11
DK3024833T3 (en) 2017-12-18
WO2015011397A1 (fr) 2015-01-29
PH12016500057B1 (en) 2016-03-28
RU2016105999A3 (ru) 2018-04-28
ME02922B (me) 2018-04-20
EA030323B1 (ru) 2018-07-31
US20180186771A1 (en) 2018-07-05
SG11201600318RA (en) 2016-02-26
EP3024833A1 (fr) 2016-06-01
TWI511969B (zh) 2015-12-11
JO3310B1 (ar) 2018-09-16
AU2014294867A1 (en) 2016-02-11
BR112016001328A2 (ru) 2017-07-25
CA2918217C (fr) 2018-06-12
CR20160031A (es) 2016-04-04
MX365916B (es) 2019-06-20
KR102007516B1 (ko) 2019-08-05
AR099913A1 (es) 2016-08-31
IL243742B (en) 2019-06-30
EP3024833B1 (fr) 2017-09-06
JP2016525536A (ja) 2016-08-25
PE20160240A1 (es) 2016-04-30
TW201504238A (zh) 2015-02-01
ZA201600350B (en) 2017-05-31
US10414754B2 (en) 2019-09-17
MD4643B1 (ru) 2019-08-31
RU2693629C2 (ru) 2019-07-03
SI3024833T1 (sl) 2017-12-29
TN2016000014A1 (fr) 2017-07-05
PL3024833T3 (pl) 2018-02-28
CU20160011A7 (es) 2016-05-30
RS56451B1 (sr) 2018-01-31
MD4643C1 (ru) 2020-03-31
LT3024833T (lt) 2017-10-25
PH12016500057A1 (en) 2016-03-28
BR112016001328B1 (pt) 2022-03-03
PT3024833T (pt) 2017-10-06

Similar Documents

Publication Publication Date Title
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201400754A3 (ru) Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015013042A (es) Compuestos organicos.
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201590534A1 (ru) Новые бициклические производные
EA201591527A1 (ru) Новые производные пиридина
EA201591748A1 (ru) Модуляторы p2x7
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201500931A1 (ru) Производные пиридин-4-ила
EA201591451A1 (ru) Модуляторы flap

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent